Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,023 across all filing types
Latest filing 2026-02-26 Annual Report
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
ucb-2025-12-31-en.xhtml
Annual Report Classification · 100% confidence The document is titled 'Integrated Annual Report 2025' and explicitly states it includes the management report, corporate governance statement, remuneration report, and financial statements. It covers the full fiscal year 2025 and provides comprehensive financial and operational data. This aligns perfectly with the definition of an Annual Report (10-K). FY 2025
2026-02-26 English
2138008J191VLSGY5A09-2025-12-31-1-en 8.xbri
Annual Report Classification · 100% confidence The document is titled 'Integrated Annual Report 2025' and explicitly states it includes the management report, corporate governance statement, remuneration report, and financial statements. It covers the full fiscal year 2025 and provides comprehensive financial and operational data. This aligns perfectly with the definition of an Annual Report (10-K). FY 2025
2026-02-26 English
UCB PR 2025 FY Results ENG.pdf
Earnings Release Classification · 95% confidence The document is a comprehensive 'Full-Year Report' for UCB for the fiscal year 2025. It contains detailed financial tables (Revenue, EBITDA, EPS), management commentary from the CEO and CFO, a breakdown of product performance, and a detailed pipeline/regulatory update. While it is titled 'Full-Year Report', it functions as the primary announcement of annual financial results rather than a full 10-K/Annual Report filing (which would typically be a much longer, multi-hundred-page regulatory document). Given the structure and content, it is classified as an Earnings Release (ER) as it provides the initial, comprehensive summary of the annual financial performance and key highlights. FY 2025
2026-02-26 English
UCB PR 2025 FY Results FR.pdf
Annual Report Classification · 100% confidence The document is a comprehensive financial report titled 'Rapport annuel UCB 2025' (UCB Annual Report 2025). It contains detailed financial statements, including revenue, EBITDA, net sales by product, and earnings per share for the fiscal year 2025 compared to 2024. It also includes management commentary, R&D pipeline updates, and regulatory information. Given the document provides substantive financial data and analysis for the full fiscal year, it is classified as an Annual Report (10-K). FY 2025
2026-02-26 French
UCB PR 2025 FY Results NL.pdf
Annual Report Classification · 100% confidence The document is a comprehensive financial report for the full fiscal year 2025, titled 'UCB financieel jaarverslag 2025'. It contains detailed financial statements, including revenue, EBITDA, net sales by product, and earnings per share, as well as management commentary on business performance, R&D updates, and future outlook. Since it covers the full fiscal year and provides substantive financial data and analysis, it is classified as an Annual Report (10-K). FY 2025
2026-02-26 Dutch
091025 EN Transparency notification FMR LLC.pdf
Major Shareholding Notification Classification · 100% confidence The document is a formal transparency notification regarding a change in major shareholding. It explicitly references the 'law of 2 May 2007 on the disclosure of large shareholdings' and details that FMR LLC has crossed a 7.5% threshold of voting rights in UCB SA/NV. This aligns perfectly with the definition of a Major Shareholding Notification (MRQ).
2025-10-09 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.